https://www.selleckchem.com/pr....oducts/Tipifarnib(R1
uggesting the importance of further work assessing the relationship between biosimilar availability and patient out-of-pocket costs. Patient-provider discussion about treatment costs has been recognized as a key component of shared clinical decision making in cancer care. This study examined the association of patient-provider cost discussion with out-of-pocket spending among cancer survivors. Using data from the 2016-2017 Medical Expenditure Panel Survey-Experiences with Cancer Survivorship Supplement, cancer survivors in t
Like
Comment
Share
